Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662444 | 1.00 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL113270 | 0.85 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30042128 | 0.85 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29362617 | 0.85 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.85 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15981181 | 0.85 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| Ammonia Solution, Strong SCHEMBL16430851 | 0.84 | KMT2A (0.57) | KMT2AFABP5FABP7EPHX2CA1 | |
| Hydrochloric Acid SCHEMBL1234617 | 0.84 | KMT2A (0.57) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL12016740 | 0.83 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2782675 | 0.83 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384754-B2 | Enrichment and tagging of glycosylated proteins | AGILENT TECHNOLOGIES, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7208573-B2 | Enrichment of phosphate peptides for proteomic analysis | AGILENT TECHNOLOGIES, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050095725-A1 | Enrichment of phosphate peptides for proteomic analysis | AGILENT TECHNOLOGIES, INC. | 2005-05-05 | — | — | US | disclosed |
| US-20050095647-A1 | Enrichment and tagging of glycosylated proteins | AGILENT TECHNOLOGIES, INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095725-A1 | Enrichment of phosphate peptides for proteomic analysis | PTMS, ACP1, CHAMP1 | KMT2A 2060/4885FABP5 1511/4885FABP7 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.